OBJECTIVE: To provide practical and up to date recommendations for evaluation, differential diagnosis, and treatment of prolactinoma and hyperprolactinemia in various clinical settings. PARTICIPANTS: Members of the Neuroendocrinology Working Group of the Spanish Society of Endocrinology. METHODS: Recommendations were formulated according to the Grading of Recommendations, Assessment, Development, and Evaluation system (GRADE) to describe both the strength of recommendations and the quality of evidence. A systematic search was made in Medline (Pubmed) for each subject, and authors' considerations were added in areas where the literature provided scarce evidence. Finally, recommendations were jointly discussed by the Working Group. CONCLUSIONS: The document provides evidence-based practical and updated recommendations for diagnosis and management of hyperprolactinemia and prolactinoma, including drug-induced hyperprolactinemia, treatment options for prolactinoma (drugs, surgery, and radiotherapy), prolactinoma in pregnancy, adverse effects of dopaminergic agents, and drug-resistant and malignant prolactinomas.
OBJECTIVE: To provide practical and up to date recommendations for evaluation, differential diagnosis, and treatment of prolactinoma and hyperprolactinemia in various clinical settings. PARTICIPANTS: Members of the Neuroendocrinology Working Group of the Spanish Society of Endocrinology. METHODS: Recommendations were formulated according to the Grading of Recommendations, Assessment, Development, and Evaluation system (GRADE) to describe both the strength of recommendations and the quality of evidence. A systematic search was made in Medline (Pubmed) for each subject, and authors' considerations were added in areas where the literature provided scarce evidence. Finally, recommendations were jointly discussed by the Working Group. CONCLUSIONS: The document provides evidence-based practical and updated recommendations for diagnosis and management of hyperprolactinemia and prolactinoma, including drug-induced hyperprolactinemia, treatment options for prolactinoma (drugs, surgery, and radiotherapy), prolactinoma in pregnancy, adverse effects of dopaminergic agents, and drug-resistant and malignant prolactinomas.
Authors: Juana Serret-Montaya; Jessie N Zurita-Cruz; Miguel A Villasís-Keever; Alejandra Aguilar-Kitsu; Claudia Del Carmen Zepeda-Martinez; Irving Cruz-Anleu; Beatriz C Hernández-Hernández; Sara R Alonso-Flores; Leticia Manuel-Apolinar; Leticia Damasio-Santana; Abigail Hernandez-Cabezza; José C Romo-Vázquez Journal: Pediatr Nephrol Date: 2020-02-10 Impact factor: 3.714
Authors: Bianca M Leca; Maria Mytilinaiou; Marina Tsoli; Andreea Epure; Simon J B Aylwin; Gregory Kaltsas; Harpal S Randeva; Georgios K Dimitriadis Journal: Sci Rep Date: 2021-05-07 Impact factor: 4.379
Authors: Chakrapani Balijepalli; Eric Druyts; Michael J Zoratti; Ping Wu; Salmaan Kanji; Kiran Rabheru; Kevin Yan; Kristian Thorlund Journal: Schizophr Res Treatment Date: 2018-04-01